VolitionRx Forges Key Partnerships Amidst Shifting Diagnostics Landscape

HENDERSON, Nevada – November 13, 2025 – VolitionRx Limited is strategically expanding its commercial footprint in the human diagnostics market, marked by recent licensing and co-marketing agreements with global healthcare leaders Werfen and Hologic. These partnerships underscore VolitionRx’s transition from a research-intensive enterprise to a commercial entity, leveraging its proprietary Nu.Q® epigenetics platform for early disease detection and monitoring. The company's Q3 2025 financial results, while showing revenue growth and reduced operating expenses, also reflect the ongoing investment in this commercialization push.

Expanding Commercial Reach Through Strategic Alliances

VolitionRx’s Q3 2025 financial report, released today, highlighted a 32% year-over-year revenue increase to $0.6 million. The company also demonstrated fiscal discipline, with operating expenses decreasing by 10% for the quarter and 18% for the first nine months of the year. This led to an 8% reduction in net loss for the quarter and a 20% improvement for the first three quarters compared to the previous year. Furthermore, net cash utilized in operating activities saw a significant 33% reduction. Subsequent to the quarter, VolitionRx secured approximately $6.1 million in net proceeds through a public offering, notably including participation from company insiders.

These financial updates were accompanied by the announcement of two pivotal agreements:
* A Research License and Exclusive Commercial Option Rights Agreement with Werfen for Antiphospholipid Syndrome (APS).
* A Co-Marketing and Services Agreement with Hologic for Volition's Nu.Q® Discover service.

These collaborations are central to VolitionRx’s strategy to capitalize on the established market presence and expertise of these multi-billion dollar diagnostic companies, thereby broadening the reach of its Nu.Q® technology.

Deep Dive into the Partnerships

The Werfen agreement positions VolitionRx to potentially revolutionize the diagnosis and management of Antiphospholipid Syndrome, a complex autoimmune disorder. “There’s a significant unmet need for more accurate and reliable biomarkers for APS,” explains one industry analyst. “If VolitionRx’s Nu.Q® H3.1 NETs assay can provide that, it could be a game-changer.” The agreement gives Werfen exclusive rights to commercialize the assay, pending further validation and regulatory approval. The initial focus will be on developing a CE-IVD marked test for use in Europe.

The partnership with Hologic takes a different approach, leveraging Hologic’s extensive reach in the drug discovery and research markets. The Nu.Q® Discover service offers a powerful platform for epigenetic profiling, allowing researchers to identify novel biomarkers and develop targeted therapies. “This is a strategic move for VolitionRx,” notes another source close to the company. “It allows them to generate revenue from their technology while also building relationships with key opinion leaders in the pharmaceutical industry.” Hologic will co-market the service to its existing customer base, accelerating its adoption and driving revenue growth.

Validating the Technology and Navigating the Competitive Landscape

VolitionRx is operating in a highly competitive market, facing challenges from established diagnostic companies and emerging biotechnology firms. The company’s key differentiator is its focus on epigenetics, the study of how genes are regulated without altering the underlying DNA sequence. “Epigenetics is a rapidly growing field, with the potential to revolutionize healthcare,” says a leading epigenetics researcher. “VolitionRx is at the forefront of this innovation, developing novel biomarkers and diagnostic tests.”

The company’s Nu.Q® platform is based on the detection of nucleosomes, the fundamental building blocks of chromatin. These nucleosomes are modified in response to various diseases, providing a unique fingerprint that can be detected in a simple blood test. VolitionRx has demonstrated the potential of its Nu.Q® platform in a variety of applications, including cancer detection, sepsis diagnosis, and autoimmune disease monitoring. “The company has strong scientific backing and an innovative approach,” states one analyst. “However, they need to demonstrate the clinical utility of their tests and secure regulatory approval to fully realize their potential.”

The company's Capture-Seq™ technology is a particularly exciting development, allowing for the concentration of chromatin fragments and tumor DNA, potentially improving the sensitivity and accuracy of liquid biopsy tests. This technology, along with ongoing clinical trials, will be critical in demonstrating the long-term value of the Nu.Q® platform and securing its position in the market.

VolitionRx is actively pursuing partnerships to accelerate the commercialization of its technology and expand its reach. The company is currently in discussions with several other diagnostic companies, and expects to announce additional partnerships in the coming months. The ability to effectively navigate the competitive landscape and establish strategic alliances will be crucial for the company's long-term success.